P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE

Autor: Hester van Zeeburg, Satwinder Kaur Singh, Eva Wagner-Drouet, Uwe Platzbecker, Tobias Holderried, Catharina VAN Elssen, Aristoteles Giagounidis, Bjorn Tore Gjertsen, Arjan van de Loosdrecht, Jeroen Rovers

Publikováno v: HemaSphere, Vol 7, p e95344a6 (2023)

Externí odkaz: https://doaj.org/article/c7e98d2e1c0d4487bcfdf3b05bb6c414

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

Autor: Isabel Leroux-Roels, Geert Leroux-Roels, Georgi Shukarev, Hanneke Schuitemaker, Conor Cahill, Richard de Rooij, Martin Struijs, Hester van Zeeburg, Jeanne-Marie Jacquet

Publikováno v: Human Vaccines & Immunotherapeutics, Vol 17, Iss 5, Pp 1366-1373 (2021)

This first-in-human study (NCT03032588), conducted in Belgium, evaluated a new inactivated poliovirus vaccines (IPV) candidate based on Sabin poliovirus strains grown on the high-yield PER.C6® cell line. Healthy adults (N = 32) were randomized (1:1)

Externí odkaz: https://doaj.org/article/8d9a181505c642feaf0a71a258804c4c

Abstract 4422: Evaluation of immune response to tumor associated antigens in patients with high grade serous ovarian cancer vaccinated intra-dermally with DCP-001, an allogeneic, cancer cell-based vaccine

Autor: Marco De Bruyn, Annegé Vledder, Rob ten Pas, Anneke Eerkens, Koen Brummel, Hester van Zeeburg, Jeroen Rovers, Hans Nijman

Publikováno v: Cancer Research. 83:4422-4422

Treatment of high grade serous ovarian cancer (HGSOC) after debulking and chemotherapy remains challenging. This phase 1 trial (NCT04739527) evaluates the use of a cell-based relapse vaccine, DCP-001, to prevent disease recurrence after primary treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35312e46a201c84a485ae054de8913a5
https://doi.org/10.1158/1538-7445.am2023-4422

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Autor: Bjørn Tore Gjertsen, Tobias A. W. Holderried, Sören Lehmann, Jacqueline Cloos, Jeroen Rovers, Uwe Platzbecker, Aristoteles Giagounidis, Eva Wagner, Arjan A. van de Loosdrecht, Hester van Zeeburg, Janine van Elssen

Publikováno v: Blood, 138. American Society of Hematology
de Loosdrecht, A A V, Cloos, J, Wagner, E M, Platzbecker, U, Holderried, T A W, van Elssen, J, Giagounidis, A, Lehmann, S, van Zeeburg, H, Rovers, J & Gjertsen, B T 2021, ' Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival ', Blood, vol. 138 . https://doi.org/10.1182/blood-2021-148333

Background. Persistence of measurable residual disease (MRD) is a poor prognostic factor and predicts relapse in acute myeloid leukemia (AML). In a phase I study, the allogeneic leukemia-derived dendritic cell vaccine, DCP-001, has shown safety and h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fed20bc37a64a9945c0eb05af845c3b2
https://research.vumc.nl/en/publications/59d1949b-7e07-4502-a18e-3947f03a032b